Cryo-Cell International, Inc. (CCEL)
Automate Your Wheel Strategy on CCEL
With Tiblio's Option Bot, you can configure your own wheel strategy including CCEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CCEL
- Rev/Share 3.9721
- Book/Share -1.8134
- PB -2.7407
- Debt/Equity -0.9457
- CurrentRatio 0.5759
- ROIC 0.0039
- MktCap 40168335.0
- FreeCF/Share 0.509
- PFCF 9.7643
- PE 312.0864
- Debt/Assets 0.2153
- DivYield 0.0805
- ROE -0.0107
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
No ratings available. |
News
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2024
Published: February 28, 2025 by: Business Wire
Sentiment: Neutral
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2024. Financial Results Revenue Consolidated revenues for fiscal 2024 were $32.0 million compared to $31.3 million for fiscal 2023. The revenues for fiscal 2024 consisted of $31.6 million in processing and storage fee revenue, $68,000 in product revenue.
Read More
About Cryo-Cell International, Inc. (CCEL)
- IPO Date 1994-04-04
- Website https://www.cryo-cell.com
- Industry Medical - Care Facilities
- CEO Mr. David I. Portnoy
- Employees 82